论文部分内容阅读
目的探讨孕妇产后HBV-DNA水平与宫内感染发生率与孕妇孕晚期时注射HBIG的相关性。方法选择我院98例HBsAg、HBeAg均阳性的晚期孕妇,均处于高风险状态,随机分为两组各49例,注射组孕晚期注射HBIG;对照组孕晚期注射生理盐水。当胎儿娩出后,分别检测两组胎儿的HBV-DNA含量,对比两组孕妇的宫内感染情况。结果根据HBV-DNA的含量发现,注射组分娩后胎儿体内的HBV-DNA含量明显降低,多处于低、极低风险,注射组宫内感染率明显少于对照组,差异有统计学意义(P<0.05)。结论在有表面抗原、e抗原均阳性的孕晚期孕妇中注射HIBG可明显阻断产后宫内感染率,降低新生儿的HBV-DNA水平,减少乙肝病毒的母婴传播,在临床中可推广。
Objective To investigate the relationship between postpartum HBV-DNA levels and the incidence of intrauterine infection in pregnant women and the third trimester of pregnancy. Methods Ninety-eight pregnant women with positive HBsAg and HBeAg in our hospital were all at high risk. They were randomly divided into two groups (n = 49). The injected group received HBIG injection in the third trimester of pregnancy. The control group received normal saline in the third trimester of pregnancy. When the fetus was delivered, the HBV-DNA levels of the two groups of fetuses were tested respectively to compare the intrauterine infection status of the two groups of pregnant women. Results According to the content of HBV-DNA, the content of HBV-DNA in fetus after injection was significantly lower, more at low and lowest risk, and the intrauterine infection rate in injection group was less than that in control group (P <0.05). Conclusion Intrauterine injection of HIBG in pregnant women with positive surface antigens and e antigen can obviously block the rate of postpartum intrauterine infection, reduce the level of HBV-DNA in neonates and reduce the mother-to-child transmission of hepatitis B virus, which can be popularized clinically.